Development Pipeline

Our systematic approach to drug discovery and development enables us to advance multiple programs efficiently from bench to bedside.

Our Development Pipeline

Our systematic approach to drug discovery and development, from target identification through clinical validation, enables us to advance multiple programs efficiently.

Protego is on track to change the treatment paradigm in AL amyloidosis:

  • Advancement of AmyLite, our proprietary assay for AL amyloidosis, which informs on the toxicity of light chains and will be used as a biomarker and patient stratification
  • Completion of our retrospective study (PRO-AL-001) across 599 AL amyloidosis patients
  • Completion of our Phase 1 (PRO-1A-101) study evaluating a first-in-class, small molecule to stabilize the misfolded light chains in AL amyloidosis
Learn More About PROT-001

1. Lambda is about 80%, the rest is kappa LC; in some cases patients present with both lambda and kappa, albeit rare (<0.2%).